Regeneron Financial Statements From 2010 to 2024

REGN Stock  USD 893.99  7.20  0.80%   
Regeneron Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Regeneron Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Regeneron Pharmaceuticals financial statements helps investors assess Regeneron Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Regeneron Pharmaceuticals' valuation are summarized below:
Gross Profit
B
Profit Margin
0.3014
Market Capitalization
98.1 B
Enterprise Value Revenue
6.9495
Revenue
13.1 B
We have found one hundred twenty available trending fundamental ratios for Regeneron Pharmaceuticals, which can be analyzed and compared to other ratios and to its competitors. Self-guided Investors are advised to check out Regeneron Pharmaceuticals' recent fundamentals against the trend between 2010 and 2024 to make sure the company can sustain itself down the road. As of the 19th of April 2024, Market Cap is likely to grow to about 40.3 B. Also, Enterprise Value is likely to grow to about 40.3 B

Regeneron Pharmaceuticals Total Revenue

13.77 Billion

Check Regeneron Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Regeneron main balance sheet or income statement drivers, such as Depreciation And Amortization of 442.1 M, Interest Expense of 76.7 M or Total Revenue of 13.8 B, as well as many exotic indicators such as Price To Sales Ratio of 6.79, Dividend Yield of 0.007 or PTB Ratio of 5.22. Regeneron financial statements analysis is a perfect complement when working with Regeneron Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement Regeneron Pharmaceuticals' financial leverage analysis and stock options assessment as well as various Regeneron Pharmaceuticals Technical models . Check out the analysis of Regeneron Pharmaceuticals Correlation against competitors.
To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.

Regeneron Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets34.7 B33.1 B13.2 B
Slightly volatile
Total Current Liabilities3.6 B3.4 B1.6 B
Slightly volatile
Total Stockholder Equity27.3 B26 B9.7 B
Slightly volatile
Property Plant And Equipment Net4.4 B4.1 B2.2 B
Slightly volatile
Cash2.9 B2.7 B1.4 B
Slightly volatile
Non Current Assets Total14.3 B13.6 B4.3 B
Slightly volatile
Cash And Short Term Investments11.4 B10.8 B5.1 B
Slightly volatile
Net ReceivablesB5.7 B2.7 B
Slightly volatile
Common Stock Shares Outstanding75.4 M113.7 M103.5 M
Slightly volatile
Liabilities And Stockholders Equity34.7 B33.1 B13.2 B
Slightly volatile
Non Current Liabilities Total3.9 B3.7 B1.8 B
Slightly volatile
Other Current Assets203.9 M386.6 M399.3 M
Slightly volatile
Total Liabilities7.5 B7.1 B3.4 B
Slightly volatile
Total Current Assets20.5 B19.5 B8.9 B
Slightly volatile
Short and Long Term Debt Total2.8 B2.7 B1.2 B
Slightly volatile
Other Current Liabilities2.5 B2.4 B738.5 M
Slightly volatile
Accounts Payable636.9 M606.6 M279.5 M
Slightly volatile
Property Plant And Equipment Gross6.4 B6.1 B2.7 B
Slightly volatile
Short Term Investments8.5 B8.1 BB
Slightly volatile
Inventory2.7 B2.6 BB
Slightly volatile
Other Liabilities854.7 M814 M575.1 M
Slightly volatile
Other Assets902.7 M859.7 M685.1 M
Slightly volatile
Long Term Debt2.1 BB1.1 B
Slightly volatile
Common Stock Total Equity91.3 K115 K97.8 K
Slightly volatile
Common Stock92.1 K115 K97.8 K
Slightly volatile
Property Plant Equipment4.5 B4.3 B2.2 B
Slightly volatile
Current Deferred Revenue481.8 M458.9 M315.8 M
Slightly volatile
Net Tangible Assets26.3 B25 B9.6 B
Slightly volatile
Long Term Debt Total2.4 B2.3 B976.6 M
Slightly volatile
Capital Surpluse12 B11.4 BB
Slightly volatile
Long Term Investments3.3 B5.4 B2.4 B
Slightly volatile
Non Current Liabilities Other675.6 M854.1 M537.9 M
Slightly volatile
Short and Long Term Debt140.8 M149 M130.7 M
Slightly volatile
Capital Lease Obligations753.7 M828 M614.4 M
Slightly volatile
Net Invested Capital29.4 B28 B9.6 B
Slightly volatile
Net Working Capital11.2 B16.1 BB
Slightly volatile
Capital Stock80 K90 K98 K
Slightly volatile

Regeneron Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization442.1 M421 M191.4 M
Slightly volatile
Total Revenue13.8 B13.1 B6.7 B
Slightly volatile
Other Operating Expenses8.4 BBB
Slightly volatile
Cost Of Revenue927.9 M883.7 M646 M
Slightly volatile
Total Operating Expenses7.4 B7.1 B3.4 B
Slightly volatile
Research Development4.7 B4.4 B2.2 B
Slightly volatile
Selling General Administrative2.7 B2.6 B1.2 B
Slightly volatile
Tax Provision584.1 M385.3 M553.9 M
Very volatile
Interest Income438.6 M417.7 M88.5 M
Slightly volatile
Reconciled Depreciation279 M408.1 M204.9 M
Slightly volatile
Non Recurring204.1 M229.6 M250 M
Slightly volatile

Regeneron Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow3.3 B3.1 B1.3 B
Slightly volatile
Depreciation442.1 M421 M171.5 M
Slightly volatile
Capital Expenditures972.7 M926.4 M435.2 M
Slightly volatile
End Period Cash Flow2.9 B2.7 B1.4 B
Slightly volatile
Stock Based Compensation929.2 M885 M445.3 M
Slightly volatile
Issuance Of Capital Stock1.3 B1.2 B637.8 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio6.797.144312.9739
Slightly volatile
Dividend Yield0.0070.00740.0077
Slightly volatile
PTB Ratio5.223.60819.939
Slightly volatile
Days Sales Outstanding166158132
Slightly volatile
Book Value Per Share25624389.9224
Slightly volatile
Invested Capital0.09890.10410.2326
Slightly volatile
Stock Based Compensation To Revenue0.09320.06750.0852
Slightly volatile
PB Ratio5.223.60819.939
Slightly volatile
EV To Sales6.797.142312.6582
Slightly volatile
Inventory Turnover0.670.70371.0381
Slightly volatile
Days Of Inventory On Hand545519514
Very volatile
Payables Turnover3.142.99342.2462
Slightly volatile
Sales General And Administrative To Revenue0.260.270.2216
Slightly volatile
Research And Ddevelopement To Revenue0.320.33840.5034
Slightly volatile
Cash Per Share10710231.7419
Slightly volatile
Payout Ratio0.330.340.5411
Slightly volatile
Days Payables Outstanding116122293
Slightly volatile
Current Ratio9.015.696.5295
Pretty Stable
Tangible Book Value Per Share24523492.3329
Slightly volatile
Receivables Turnover2.22.31452.8605
Slightly volatile
Graham Number473450199
Slightly volatile
Shareholders Equity Per Share25624389.9224
Slightly volatile
Debt To Equity0.09890.10410.2326
Slightly volatile
Revenue Per Share12912361.1128
Slightly volatile
Debt To Assets0.130.08170.1427
Slightly volatile
Operating Cycle710676615
Slightly volatile
Price Book Value Ratio5.223.60819.939
Slightly volatile
Days Of Payables Outstanding116122293
Slightly volatile
Dividend Payout Ratio0.330.340.5411
Slightly volatile
Ebt Per Ebit1.411.03760.9986
Slightly volatile
Company Equity Multiplier1.911.27361.6067
Slightly volatile
Long Term Debt To Capitalization0.150.09430.1483
Slightly volatile
Total Debt To Capitalization0.150.09430.1746
Slightly volatile
Debt Equity Ratio0.09890.10410.2326
Slightly volatile
Quick Ratio5.814.82334.5381
Slightly volatile
Net Income Per E B T1.10.94150.8794
Very volatile
Cash Ratio0.760.79751.7843
Slightly volatile
Days Of Inventory Outstanding545519514
Very volatile
Days Of Sales Outstanding166158132
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.330.79830.9192
Pretty Stable
Price To Book Ratio5.223.60819.939
Slightly volatile
Fixed Asset Turnover3.323.16352.913
Slightly volatile
Debt Ratio0.130.08170.1427
Slightly volatile
Price Sales Ratio6.797.144312.9739
Slightly volatile
Asset Turnover0.280.39650.5373
Pretty Stable
Price Fair Value5.223.60819.939
Slightly volatile

Regeneron Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap40.3 B38.4 B37.2 B
Slightly volatile
Enterprise Value40.3 B38.4 B37.1 B
Slightly volatile

Regeneron Fundamental Market Drivers

Forward Price Earnings20.1207
Cash And Short Term Investments10.8 B

Regeneron Upcoming Events

2nd of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
2nd of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Regeneron Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Regeneron Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Regeneron Pharmaceuticals investors use historical funamental indicators, such as Regeneron Pharmaceuticals's revenue or net income, to determine how well the company is positioned to perform in the future. Although Regeneron Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Regeneron Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Regeneron Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Regeneron Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Regeneron Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue458.9 M481.8 M
Total Revenue13.1 B13.8 B
Cost Of Revenue883.7 M927.9 M
Stock Based Compensation To Revenue 0.07  0.09 
Sales General And Administrative To Revenue 0.27  0.26 
Research And Ddevelopement To Revenue 0.34  0.32 
Capex To Revenue(0.07)(0.07)
Revenue Per Share 122.94  129.08 
Ebit Per Revenue 0.31  0.32 

Currently Active Assets on Macroaxis

When determining whether Regeneron Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regeneron Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regeneron Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regeneron Pharmaceuticals Stock:
Check out the analysis of Regeneron Pharmaceuticals Correlation against competitors.
To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.
Note that the Regeneron Pharmaceuticals information on this page should be used as a complementary analysis to other Regeneron Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.

Complementary Tools for Regeneron Stock analysis

When running Regeneron Pharmaceuticals' price analysis, check to measure Regeneron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regeneron Pharmaceuticals is operating at the current time. Most of Regeneron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Regeneron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regeneron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Regeneron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Transaction History
View history of all your transactions and understand their impact on performance
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Money Managers
Screen money managers from public funds and ETFs managed around the world
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Is Regeneron Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.03)
Earnings Share
34.78
Revenue Per Share
122.935
Quarterly Revenue Growth
0.006
Return On Assets
0.0849
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.